Molecular imaging coupled to pattern recognition distinguishes response to temozolomide in preclinical glioblastoma

Research output: Contribution to journalArticleResearchpeer-review

13 Citations (Scopus)

Abstract

© 2014 John Wiley & Sons, Ltd. Non-invasive monitoring of response to treatment of glioblastoma (GB) is nowadays carried out using MRI. MRS and MR spectroscopic imaging (MRSI) constitute promising tools for this undertaking. A temozolomide (TMZ) protocol was optimized for GL261 GB. Sixty-three mice were studied by MRI/MRS/MRSI. The spectroscopic information was used for the classification of control brain and untreated and responding GB, and validated against post-mortem immunostainings in selected animals. A classification system was developed, based on the MRSI-sampled metabolome of normal brain parenchyma, untreated and responding GB, with a 93% accuracy. Classification of an independent test set yielded a balanced error rate of 6% or less. Classifications correlated well both with tumor volume changes detected by MRI after two TMZ cycles and with the histopathological data: a significant decrease (p<0.05) in the proliferation and mitotic rates and a 4.6-fold increase in the apoptotic rate. A surrogate response biomarker based on the linear combination of 12 spectral features has been found in the MRS/MRSI pattern of treated tumors, allowing the non-invasive classification of growing and responding GL261 GB. The methodology described can be applied to preclinical treatment efficacy studies to test new antitumoral drugs, and begets translational potential for early response detection in clinical studies.
Original languageEnglish
Pages (from-to)1333-1345
Number of pages13
JournalNMR in Biomedicine
Volume27
Issue number11
DOIs
Publication statusPublished - 1 Nov 2014

Keywords

  • DMSO
  • GL261 glioblastoma
  • Pattern recognition
  • Perturbation-enhanced MRSI
  • Therapy response detection

Fingerprint

Dive into the research topics of 'Molecular imaging coupled to pattern recognition distinguishes response to temozolomide in preclinical glioblastoma'. Together they form a unique fingerprint.

Cite this